2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1351

Minimal Clinically Important Improvement (MCII) of RAPID3 (ROUTINE ASSESSMENT OF PATIENT INDEX DATA 3), an INDEX of ONLY Patient Self-Report Scores in Rheumatoid Arthritis (RA): Similar Performance to DAS28 and CDAI
Abstract Number: 2621

Minimal Renal Affection in Patients with Systemic LUPUS Erythematosus: Characteristics and Evolution
Abstract Number: 567

Minor Salivary Gland Histopathology, Major Salivary Gland Ultrasonography, and Secretory Function in Smoking Patients with Primary Sjögren’s Syndrome
Abstract Number: 643

Mir-10b-5p Is a IL-22 Regulator in CD4+T Cells from Ankylosing Spondylitis
Abstract Number: 63

MiR-146a a Key Player in Bone Metabolism
Abstract Number: 2436

MiR-146a Upregulates the TLR4/NF-κb Signaling Pathway to Promote Cytokine Expression and Synovial Fibroblast Proliferation in Rheumatoid Arthritis
Abstract Number: 301

MiR-221-3p Overexpression Impairs Anti-Inflammatory Activity of TLR4-Stimulated M2-Macrophages
Abstract Number: 1715

Mitochondrial DNA Mutations and Respiratory Chain Dysfunction in Lung Fibrosis of Systemic Sclerosis
Abstract Number: 1011

Mitochondrial Haplogroups-Mediated Methylation Regulates Apoptosis in Osteoathritis Cartilage
Abstract Number: 1933

Mitochondrial ROS Activate the p38-MAPK/AP1 Pathway to Induce the Expression of Matrix Metalloproteases and IL-6 in Human Chondrocytes
Abstract Number: 1417

Mitophagy Defect in Fibroblast-like Synoviocytes of Rheumatoid Arthritis Is Improved By Pyruvate Treatment
Abstract Number: 14L

Miv-711, a Novel Cathepsin K Inhibitor Demonstrates Evidence of Osteoarthritis Structure Modification: Results from a 6 Month Randomized Double-Blind Placebo-Controlled Phase IIA Trial
Abstract Number: 2124

Mixed Connective Tissue Disorder Has Higher Prevalence of Arthritis and Use of Methotrexate Than Systemic Lupus Erythematosus
Abstract Number: 2326

Modeling Transcriptional Rewiring in Neutrophils through the Course of Treated Juvenile Idiopathic Arthritis
Abstract Number: 2987

Moderate and Serious Psychological Distress Among US Adults with and without Arthritis, 2002 to 2015

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].